CIE Advisory Board Profile
President & CEO
NextWave Pharmaceuticals (Sold to Pfizer, 2012)
Jay Shepard joined NextWave Pharmaceuticals (sold to Pfizer in 2012) as President & CEO in 2010. He has more than 25 years experience in the pharmaceutical, biotechnology and drug delivery arenas. In addition to his responsibilities to NextWave Pharmaceuticals, Jay maintains a consulting relationship with Sofinnova Ventures in his capacity as an Executive in Residence, a position he has held since 2008.
Before joining Sofinnova Ventures, Jay was President and CEO of Ilypsa, a nephrology therapeutics company acquired by Amgen for $420 million. He then helped with Ilypsa’s spin-out of Relypsa, serving as interim President and CEO, and today remains involved as a board member. Before Ilypsa, Jay served as Vice President, Commercial Operations at Telik, where he was responsible for all activities relating to market preparation toward the launch of the company’s lead oncology compounds. He was also Vice President of ALZA Pharmaceuticals’ Oncology Business Unit, having held leadership positions of increasing responsibility in the establishment and operation of ALZA’s specialty pharmaceutical sales and marketing group.
Jay began his career in pharmaceutical sales and marketing at Ortho Pharmaceutical and Syntex Laboratories. He holds a B.S. in business administration from the University of Arizona and serves on the Advisory Board of the Center for Innovation and Entrepreneurship at Santa Clara University.